Why Is McKesson (MCK) Up 5.7% Since Last Earnings Report?
McKesson (MCK) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Positive
MCK
McKesson CorporationNYSEHEALTHCAREMEDICAL DISTRIBUTION
Key Statistics
Market Cap
$105.86B
P/E Ratio
24.33
EPS
$37.32
Beta
0.31
52W High
$996.84
52W Low
$684.98
50-Day MA
$847.25
200-Day MA
$843.22
Dividend Yield
0.36%
Profit Margin
1.12%
Forward P/E
20.70
PEG Ratio
1.75
About McKesson Corporation
McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.
Fundamentals
| Revenue (TTM) | $410.98B |
| Gross Profit (TTM) | $14.93B |
| EBITDA | $7.07B |
| Operating Margin | 1.35% |
| Return on Equity | 0.00% |
| Return on Assets | 4.74% |
| Revenue/Share (TTM) | $3367.33 |
| Book Value | $-36.55 |
| Price-to-Book | 5.04 |
| Price-to-Sales (TTM) | 0.26 |
| EV/Revenue | 0.277 |
| EV/EBITDA | 15.19 |
| Quarterly Earnings Growth (YoY) | -17.60% |
| Quarterly Revenue Growth (YoY) | 7.70% |
| Shares Outstanding | $116.59M |
| Float | $116.39M |
| % Insiders | 0.06% |
| % Institutions | 93.62% |
Historical Volatility
HV 10-Day
27.39%
HV 20-Day
29.57%
HV 30-Day
34.55%
HV 60-Day
32.00%
HV Rank
81.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($986.94 target)
3
Strong Buy11
Buy4
HoldLatest News
Here's Why McKesson (MCK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research9/3/2026Positive
Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson
A prolific hacking group has taken credit for last week's cyberattack against U.S. pharmaceutical distribution giant McKesson, leading to the latest spill of highly sensitive health data by an American healthcare company in recent months.
TechCrunch8/31/2026Negative
McKesson to Acquire Precision Medicine Group to Strengthen Services
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
Zacks Investment Research8/27/2026Positive
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
Zacks Investment Research8/25/2026Neutral
McKesson to buy Precision Medicine Group in about $2.25 billion deal
U.S. drug distributor McKesson said on Tuesday it would buy clinical research and biopharma commercialization services provider Precision Medicine Group in a deal valued at about $2.25 billion.
Reuters8/25/2026Positive
McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate
McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.
Zacks Investment Research8/24/2026Positive
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?
McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.
Zacks Investment Research8/24/2026Positive
Here's Why McKesson (MCK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research8/10/2026Positive
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
Zacks Investment Research8/7/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MCK and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026